41 results about "Viral replication" patented technology

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

This disclosure relates to a method for preparing intermediates useful for preparing compounds that inhibit the function of human immunodeficiency virus (HIV) during the viral replication cycle, such as by disrupting the function of the HIV capsid shell. [Formula 1] JPEG2026524821000058.jpg39145

This invention relates to the fields of environmental monitoring and biosafety technology, and in particular to a viral aerosol sampling patch for face masks, comprising: a capture layer for intercepting viral aerosol particles in the air; a culture layer disposed inside the capture layer, the culture layer comprising a culture unit supporting the virus to maintain activity and replicate in the presence of a host, a host bacterium sensitive to the virus, and a visual indicator indicating viral replication or host response; and a base layer disposed inside the culture layer; the sampling patch is fixed to the face mask through the base layer, and viral aerosol collection is achieved without external power through the capture layer, and countable detection results are generated after sampling through the culture layer; utilizing the airflow and humidity conditions naturally formed during wearing, effective interception, activity preservation, and visual detection of viral aerosols are achieved without complex equipment and additional operating steps, and the operation is simple and repeatable.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

The present invention relates to a method for detecting and / or selecting S. lycopersicum plants resistant to Tomato Brown Rugose Fruit Virus (TBRFV), which inhibit, reduce, or delay virus replication, characterized in that it comprises the steps of: a) detecting at least one of the following markers: T allele of TO-0122252 (SEQ ID NO:7), C allele of TO-0144317 (SEQ ID NO:8), T allele of TO-0142270 (SEQ ID NO:9), G allele of TO-0142294 (SEQ ID NO:10), A allele of TO-0142303 (SEQ ID NO:11), A allele of TO-0142306 (SEQ ID NO:12), G allele of TO-0182276 (SEQ ID NO:13), G allele of TO-0181040 (SEQ ID NO:14), G allele of TO-0123057 (SEQ ID NO:15), A allele of TO-0125528 (SEQ ID NO:16), C allele of TO-0162432 (SEQ ID NO:17) and T allele of TO-0162427 (SEQ ID NO:18), and b) detect the homozygous presence of the Tm-1 gene, preferably by detecting the A allele of the SNP marker TO-0200838 (SEQ ID NO:21).

This invention discloses an attenuated chikungunya virus expressing a nanoluciferase gene, the nucleotide sequence of which is shown in SEQ ID NO:1. It is constructed by attenuating the virulence of the chikungunya virus LR2006-OPY1 strain by deleting 61 amino acids from positions 323 to 383 of the nsP3 protein and inserting a nanoluciferase gene after position 490 of the nsP3 protein. This virus model maintains similar growth characteristics to the wild-type virus but with significantly improved safety. Viral replication can be monitored in real time by detecting luciferase activity, making it suitable for drug screening at both cellular and animal levels. This provides an efficient and safe technical platform for the development of antiviral drugs against chikungunya virus.

The application belongs to the technical field of genetic engineering, and particularly relates to application of TRIM25 gene as a target point in inhibition of H9N2 influenza virus replication.(1) The application finds that inhibition or silencing of the TRIM25 gene can inhibit replication of the H9N2 influenza virus, and TRIM25 can be used as a target point for screening drugs for inhibiting replication of the H9N2 influenza virus;(2) The application provides an sgRNA specifically targeting the TRIM25 gene, and complete knockout of the TRIM25 gene is realized by combining CRISPR-Cas9 technology, and a monoclonal cell line obtained has a resistance phenotype to the H9N2 influenza virus, thereby providing a new idea for prevention and control of the H9N2 influenza virus;(3) The application finds that a TRIM25 cell line with overexpression can promote replication of the H9N2 influenza virus, and TRIM25 or an expression promoter thereof can be used as a replication or production enhancer of the H9N2 influenza virus.

This application discloses a PB2 / JAK dual-target inhibitor and its application. The general formula of the PB2 / JAK dual-target inhibitor is shown in formula (I) or formula (II). The PB2 / JAK dual-target inhibitor of this application has both antiviral and anti-inflammatory activities, providing a new drug for the prevention and treatment of PB2-dominated viral replication-related diseases or JAK pathway-dominated inflammation-related diseases.

This invention discloses an antisense oligonucleotide targeting and inhibiting the RdRp gene and its applications. This study designed and screened a series of antisense oligonucleotides (ASOs) targeting the highly conserved SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), and systematically evaluated their antiviral effects against various SARS-CoV-2 variants. Experimental results show that the designed ASO molecules, especially RDRP-5, exhibit significant viral inhibitory activity at multiple experimental levels (including reporter gene systems, viral replicon models, and true viral infection experiments).

This invention discloses a method for preparing pet stem cell exosomes, belonging to the field of animal medicine technology. This invention treats stem cells with an inducing agent to secrete exosomes with high TFR expression on their surface. These exosomes specifically target the conserved region of the NS1 gene, a non-structural protein of the parvovirus family, allowing the internally loaded siRNA and trefoil factor 3 to target and enter infected cells, directly inhibiting viral replication at the gene level to treat feline panleukopenia virus (FPV) and canine parvovirus infections and alleviate sequelae. This invention solves the problems of existing technologies, such as difficulty in targeting, lack of specific drugs, reliance on intensive supportive care leading to a short treatment window, inability to directly clear the virus, risk of cross-infection, and potential long-term sequelae. It has the potential to be applied to the preparation of drugs for treating canine parvovirus and feline panleukopenia.

The application discloses application of lapatinib in preparation of a rabies virus resisting medicine, and first discovers the rabies virus resisting activity of lapatinib, breaks the limitation of lapatinib only being used for treating tumors, and first proves the role of lapatinib in inhibiting rabies virus replication through in-vivo and in-vitro experiments, develops the potential application value of lapatinib in early treatment after rabies virus exposure, and provides a new use of lapatinib, i.e., using lapatinib as a candidate medicine for rabies treatment, especially specific treatment in the early stage of rabies virus infection, and fills the blank of specific treatment medicines after rabies virus exposure.

The application discloses a method for detecting viruses and virus replication in media based on Small-RNA high-throughput sequencing. The application belongs to the technical field of virus detection, and the method for identifying virus types in a to-be-detected sample by Small-RNA sequencing developed by the application comprises the following steps: 1) extracting total RNA from a virus-infected to-be-detected sample, constructing a cDNA library, and separating small RNA sequence fragments from the cDNA library; 2) downloading virus sequences and classification databases from GenBank, and comparing the small RNA sequence fragments with virus sequence files; 3) comparing a contigs3 file with a virus nucleic acid database, selecting sequences with the minimum e value in the comparison results in the contigs3 file, calculating the coverage of the contigs3 sequences in corresponding virus genomes, distinguishing virus information with a coverage threshold, and deducing the virus source of the small RNA sequence.

This invention provides an attenuated vaccine against Coxsackievirus A6 (CVA6), its preparation method, and its application. By comparing a highly pathogenic clinical isolate (CVA6-HeB) with an attenuated strain (CVA6-TW141), the genetic basis of CVA6 virulence was systematically studied. This invention located the core virulence determinant to the P1 capsid region and identified a key lethal amino acid residue (VP3-238) that significantly weakens viral replication in target tissues. Based on this discovery, this invention designed and validated a candidate attenuated live vaccine with significantly reduced lethality.

The application discloses a Marburg virus-based micro-genome replication-defective system and application thereof, and belongs to the field of biological medicine. The system significantly improves the expression efficiency and signal-to-noise ratio of a model reporter gene through a codon optimization strategy. Experimental verification shows that the model can safely simulate the MARV genome replication and transcription process under a biosafety level 2 (BSL-2) condition, and has high specificity and sensitivity. Through parallel verification of positive drugs such as ribavirin, suramin sodium salt and negative controls such as oseltamivir, it is confirmed that the model can accurately and quantitatively evaluate the activity of small-molecule drugs targeting the replication link of the virus and calculate EC50. The model provides a safe and efficient platform for the study of the MARV replication mechanism and the high-throughput screening of antiviral drugs, breaks through the limitation of a biosafety level 4 laboratory, and has important scientific research and application value.

The application discloses a metal polypeptide compound and a preparation method and application thereof. The preparation method of the metal polypeptide compound provided by the application comprises the following steps: obtaining RLRGG-PPh2 by condensation reaction of polypeptide RLRGG and 3-(diphenylphosphino)propionic acid; and obtaining RLRGG-PPh2Au by reaction of RLRGG-PPh2 and chloro(dimethylsulfide)gold (I). The metal polypeptide compound provided by the application not only retains the inhibitory activity of gold (I) complex on viral protease, but also utilizes the targeted delivery characteristics of RLRGG polypeptide, improves the effective action probability of the metal active center at the key action site of the virus, and realizes the synergistic inhibition on the viral replication process. Experimental results show that the metal polypeptide can effectively reduce the viral infection level, and inhibit the viral replication activity through multi-target action and multi-regulation mechanism.

The application discloses a PKR gene knockout cell line and a construction method and application thereof. The construction method comprises the following steps: A1, designing sgRNA primers for PKR gene knockout; A2, performing single enzyme cutting treatment on LentiCRISPR v2 plasmid to obtain enzyme cutting products; A3, performing annealing hybridization reaction by using the synthesized sgRNA primers to obtain annealing hybridization products; A4, performing a ligation reaction on the enzyme cutting products and the annealing hybridization products, and transforming the obtained reaction products into competent cells to obtain a recombinant transfer plasmid; and A5, after performing lentivirus packaging on the recombinant plasmid, infecting A549 cells by using the obtained lentivirus liquid to obtain the PKR gene knockout cell line. The application successfully constructs the A549 cell line with the PKR stable knockout, the A549 cell line can inhibit the type I interferon induced by NDV, promote virus replication and induce more serious cell death, and thus can be applied to the development of NDV vaccines.

This invention discloses a homogeneous polysaccharide from *Rhizoctonia solani* that exhibits antiviral activity against human cytomegalovirus in both the virus-cell binding stage and the post-virus invasion stage, along with its preparation method and applications. This polysaccharide is a homogeneous polysaccharide Ts1-1A extracted, isolated, and purified from the fruiting bodies of *Rhizoctonia solani*. *Rhizoctonia solani* homogeneous polysaccharide Ts1-1A is a novel heteropolymer containing partially branched chains, with its main chain consisting of →3)-α-Fuc p -(1→and→6)-α-Gal p -(1→ Composed in a 1:1 ratio, with T-α-Man branches p -(1→, connected to the 2nd and 3rd positions of the same Gal on the main chain, with an average of 2 branches replacing every 16 sugar residues in the main chain. During the viral attachment period, it can prevent the virus from adsorbing onto cell surface receptors by binding to the virus. At the same time, after entering the cell, it can inhibit viral replication through antioxidant effects, thereby exerting an antiviral effect.

This invention discloses the application of ZAK inhibitors in the preparation of drugs for treating EV71 virus infection, relating to the biomedical field. The ZAK inhibitors exert their effects by inhibiting the ZAK-p38 MAPK signaling pathway and by inhibiting the ZAKα-mediated ribosomal toxicity stress response (RSR). The ZAK inhibitor is nilotinib or a pharmaceutically acceptable salt thereof. Cellular and animal experiments of this invention demonstrate that EV71 infection activates the ZAKα-mediated p38 MAPK pathway (RSR), promoting viral replication and leading to multi-organ damage. ZAK inhibitors (such as nilotinib) can inhibit this pathway, reduce the expression of the viral protein VP1, and improve infection-induced renal function damage, metabolic disorders, and muscle damage. Therefore, ZAK inhibitors can be used to prepare anti-EV71 drugs.

This invention relates to the field of biotechnology, specifically to a method for elucidating the interaction complex between the BTVNS2 protein and host cells. The method involves constructing an initial list of host proteins through cross-validation using affinity purification-mass spectrometry and biotinylate proximity labeling-mass spectrometry. Weighted scoring and ranking are then performed based on quantitative mass spectrometry data and functional relevance. Binding characteristics are validated and quantified intracellularly and extracellularly using immunoprecipitation and biophysical techniques, respectively. The complex is assembled in vitro, and its high-resolution three-dimensional structure is resolved using single-particle cryo-electron microscopy. This invention addresses key problems in existing technologies, such as incomplete capture of interacting proteins, high false-positive rates, blind functional screening, and difficulty in obtaining samples suitable for high-resolution structural analysis due to reliance on single methods. It systematically identifies key host factors and ultimately reveals the precise structure of the interaction interface at the atomic level, providing a foundation for understanding viral replication mechanisms and developing antiviral strategies.

The present disclosure relates to RNA sequences, compositions, and methods of use to prevent viral replication, prevent RNA polymerase activity, activate innate immune responses, or combinations thereof.

The invention relates to a method for generating in a single step a library of recombinant baculoviruses for screening for a protein of interest, starting from a pooled-library of poly-nucleotides each encoding a different protein. Insect cells are infected with a pooled-library of baculoviruses at a very low multiplicity of infection (MOI) leading to the situation where the majority of cells are infected by a single baculovirus. The pool of cells is then treated with a viral inhibitor which prevents secreted baculoviruses from penetrating other cells without affecting, either the capacity of the cell to express the target protein, nor intracellular viral replication and accumulation.

This invention relates to the field of antiviral drugs, specifically a dynamic equilibrium regulatory model for SUMOylation and K48K63 ubiquitination of the SARS-CoV-2 N protein, a targeted regulatory agent, and an application method. This invention uses a SUMOylation pathway inhibitor to block SUMOylation modification of the N protein; and / or in combination with a deubiquitinating enzyme inhibitor to maintain endogenous K48 ubiquitination signaling. By inhibiting SUMOylation, its spatial shielding of K48 ubiquitination is removed, and the N protein is rapidly degraded using the cellular endogenous ubiquitin-proteasome system, thereby inhibiting viral replication. This invention provides a pharmaceutical composition containing the above-mentioned active ingredients, a kit for detecting the modification status of the N protein, and its application in the preparation of anti-SARS-CoV-2 drugs. The technical solution of this invention is simple and feasible, the raw materials are readily available, no complex genetic engineering vector construction is required, and it has significant antiviral effects and extremely high transformation value.

This invention belongs to the field of pharmaceutical technology, specifically relating to heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, their preparation methods, and uses. The compounds of this invention are heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, and also include their pharmaceutical salts, hydrates, and solvates, as well as their polycrystalline or cocrystalline forms, and their precursors and derivatives with similar biological functions. These compounds or combinations thereof can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that these small molecules possess strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

This invention discloses a drug for viral myocarditis, relating to the field of drug preparation technology. The drug comprises at least one of imperatorin, isochorin, and epicatechin gallate. This drug can effectively inhibit viral replication in myocardial tissue, significantly reduce serum pro-inflammatory factor levels, alleviate inflammatory infiltration, and significantly reduce cell apoptosis, thereby exerting a therapeutic effect on viral myocarditis. This invention solves the problem of the lack of highly effective multi-target viral myocarditis drugs in the prior art.

This invention provides a drug for combating SARS-CoV-2 and antibacterial agents, and a method for preparing the same. The method involves reacting L-cysteine ​​and copper sulfate under alkaline conditions to prepare negatively charged nano-Cu2S. This nano-Cu2S reacts with the main protease M of SARS-CoV-2. pro and papain PL pro The nano-Cu2S binds to the main protease M of the SARS-CoV-2 virus to inhibit viral replication. pro and papain PL pro The dissociation constants between the components are all less than 0.001 nM. Simultaneously, nano-Cu2S exhibits antibacterial activity, inhibiting the proliferation of various bacteria. The synthesis process of the drugs for combating COVID-19 and antibacterial purposes according to this invention is simple and suitable for large-scale production. Nano-Cu2S has low toxicity and good biosafety, and can be widely used in the coatings and disinfection fields to inhibit the spread of viruses and bacteria.

The application provides application of a compound Incyclinide in preparation of an anti-dengue virus drug, and belongs to the technical field of biological medicines.The dengue virus is a dengue virus with a serum type of DENV-2.The anti-virus activity experiment determines that the compound Incyclinide can significantly inhibit replication of the dengue virus under conditions of concentrations of 50 μM, 20 μM and 10 μM, and the compound Incyclinide has the effect of inhibiting replication of the dengue virus and can be used for preparation of the anti-dengue virus drug.

The application belongs to the technical field of medicine preparation, and specifically discloses an interfering peptide for inhibiting mitochondrial autophagy induced by a coronavirus nucleocapsid protein, and a preparation method and application thereof. The interfering peptide (named ISQORbeta2) is composed of D-type amino acids, and the structure comprises: a polypeptide sequence as shown in SEQ ID NO:1; and 5-isothiocyanate fluorescein covalently connected to the N terminal of the polypeptide. The interfering peptide effectively inhibits mitochondrial autophagy activation, intracellular H2S accumulation, mitochondrial potential depolarization, and restores the expression of innate immune molecules by competitively blocking the interaction between IBV-N and SARS-CoV-2-N and sulfide quinone oxidoreductase, thereby resisting viral replication and reducing lung injury. The application solves the problems of the prior art, such as difficulty in blocking protein interaction, poor peptide stability, and inability to effectively restore the immune pathway, and has the advantages of high in-vitro and in-vivo stability, small toxic and side effects, and great potential for drug development.